The days of simply determining the market demand for a new drug as a function of price and choosing the revenue or profit optimizing point are gone. In our new environment, an explicit rationale, the “value-based price” has become a prerequisite for enabling conversation with payers while policy-makers seem poised to limit the pricing corridors with increased government intervention. Outcomes-based agreements aim at expanding patient access, which benefits manufacturers, and limits payers’ financial risk by guaranteeing clinical outcomes or restricting budgets.
Watch this short video by Oliver Leatham, VP, Global Head of Commercial Strategy and EU Value & Access as he elaborates on four payment models that have emerged in recent years and their real world applications.
About Our Speaker
Oliver Leatham is VP, Global Head of Commercial Strategy and EU Value & Access. He has worked for over 25 years in the Pharmaceutical and Healthcare Consulting Industry. He has built and led EU and Global Market Access Teams and had been involved in a number of successful new product launches in oncology, rare diseases, immunotherapy and cardiovascular disease. Oliver and his Team have been involved in the creation, negotiation,> and execution of some of the first innovative contracting and outcomes-based agreements in Europe, that have led to both early and optimized access for the manufacturer. Oliver leads a Global Team of Subject Matter Experts in HEOR, HTA, Pricing, Value Strategy and Market Access.